Biomarker · Gene alteration

EGFR mutation (any sensitizing or resistance mutation)

Somatic mutations of the EGFR tyrosine kinase domain detected by sequencing or PCR in tumor tissue or plasma; used as a predictive marker for EGFR tyrosine kinase inhibitors, chiefly in non-small cell lung cancer.

CI-BIO-00000008EGFR graph →NCIt C98357

Also calledEGFR-mutant · EGFR-mutated · EGFR activating mutation

Derived

Associated cancers (20)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Lung Non-Small Cell Carcinoma	152	149	3	—	28 / 52 / 32 / 39 / 1
Lung Adenocarcinoma	46	44	2	—	1 / 18 / 25 / 2 / 0
Malignant Colorectal Neoplasm	17	17	—	—	0 / 5 / 4 / 7 / 1
Malignant Neoplasm	14	14	—	—	0 / 0 / 0 / 14 / 0
Head and Neck Squamous Cell Carcinoma

Derived

Drugs with predictive evidence (39)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
ErlotinibSmall Molecule	99	78	21	A	71 / 21	Colon Adenocarcinoma, Glioblastoma, High-Grade Glioma, NOS, Lung Adenocarcinoma +6
GefitinibSmall Molecule	69	59	10

Curated evidence

Predictive evidence items (252)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 252 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR Expression1
Lapatinib

Regulatory

Approvals mentioning the linked drugs (475)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpd

Clinical trials

Active trials (936)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 468 recruiting · 247 active phase 3 · 3,992 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 101–150 of 936 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07831187	Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence	not yet recruiting	Phase 1 / Phase 2	96	First Affiliated Hospital of Wenzhou Medical University

Literature

Linked publications (141)

Publications linked to the scope gene(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–25 of 141 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

EGFR T790M resistance mutation in non small-cell lung carcinoma.
· Clin Chim Acta · 2015 · PMID 25668228 · validated civic_curation pubmed
Osimertinib: First Global Approval.
· Drugs · 2016 · PMID 26729184 · validated civic_curation pubmed
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
· N Engl J Med · 2017 · PMID 27959700 · validated civic_curation pubmed
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
· Oncologist · 2014 · PMID 24868098 · validated

EGFR Overexpression3
Nimotuzumab	Esophageal Squamous Cell CarcinomaALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID783 55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to mod… (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC	civic
Cetuximab	Head and Neck Squamous Cell Carcinoma	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID692 EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcino… (full text at CIViC) PMID 23265711 · Licitra et al., 2013 · Open in CIViC	civic
Cetuximab + DocetaxelCombination	Head and Neck Squamous Cell Carcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID849 47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFR. EGFR expression had no imp… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC	civic

EGFR VIII5
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID772 49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort o… (full text at CIViC) PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC	civic
Erlotinib + GefitinibSubstitutes	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID1128 Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment w… (full text at CIViC) PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC	civic
Rindopepimut	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID971 In a Phase II clinical trial, patients with Glioblastoma Multiforme (GBM), positive for EGFR VIII deletion mutation (N=65), were treated with the Rindopepimut cancer vaccine, and standard adjuvant te… (full text at CIViC) PMID 25586468 · Schuster et al., 2015 · Open in CIViC	civic
Cetuximab + DocetaxelCombination	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Resistance	2	accepted	EID848 47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression wa… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC	civic
Erlotinib	High-Grade Glioma, NOS	Predictive	D	Supports Sensitivity Response	3	accepted	EID4500 In an in vitro study, a Ba/F3 cell line expressing EGFR vIII demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic

EGFR L858R9
Erlotinib	High-Grade Glioma, NOS	Predictive	D	Supports Sensitivity Response	3	accepted	EID4295 In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assesse… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic
Afatinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID879 A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID883 In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were … (full text at CIViC) PMID 22452895 · Yang et al., 2012 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID982 Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364… (full text at CIViC) PMID 24439929 · Wu et al., 2014 · Open in CIViC	civic
Cetuximab	Lung Adenocarcinoma	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID4292 In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by asse… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
Erlotinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID4290 In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 mon… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID4291 In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment (IC50 26.9 ± 12.4nM). EGFR L858R was used as a positive control for comparing sensiti… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
Gefitinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID2634 In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response… (full text at CIViC) PMID 22370314 · Han et al., 2012 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID6183 In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy … (full text at CIViC) PMID 27022112 · Urata et al., 2016 · Open in CIViC	civic

EGFR Exon 19 Deletion6
Afatinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID880 A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 9… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID882 In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In to… (full text at CIViC) PMID 22452895 · Yang et al., 2012 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID981 Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364… (full text at CIViC) PMID 24439929 · Wu et al., 2014 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID983 In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemothe… (full text at CIViC) PMID 25589191 · Yang et al., 2015 · Open in CIViC	civic
Erlotinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	—	accepted	EID4766 In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 d… (full text at CIViC) PMID 27566387 · Kanemaru et al., 2016 · Open in CIViC	civic
Gefitinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID2519 In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response… (full text at CIViC) PMID 22370314 · Han et al., 2012 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Cisplatin	CA Health Canada	—	Marketed in Canada as PLATINOL AQ INJ 1MG/ML (DIN 00788740) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 30, 2001	Dec 31, 1988	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJ 1MG/ML (DIN 00692743) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 13, 1998	Dec 31, 1986	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJ 0.5MG/ML (DIN 00644293) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996	Dec 31, 1985	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02409186) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02422034) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02393832) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as PMS-CISPLATIN (DIN 02409194) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Aug 3, 2017	—	health-canada-dpd
Crizotinib	CA Health Canada	—	Marketed in Canada as XALKORI (DIN 02384256) under ATC L01ED01 CRIZOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 10, 2012	health-canada-dpd
Crizotinib	CA Health Canada	—	Marketed in Canada as XALKORI (DIN 02384264) under ATC L01ED01 CRIZOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 10, 2012	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02458020) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 17, 2017	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02439336) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 2, 2016	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02437031) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Oct 29, 2025	Feb 27, 2015	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02412233) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 17, 2018	Mar 28, 2014	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02412225) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 17, 2018	Mar 28, 2014	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION USP (DIN 02361957) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 1, 2011	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TAXOTERE (DIN 02177080) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 31, 2020	Dec 31, 1995	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TAXOTERE (DIN 02177099) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 30, 2018	Dec 31, 1995	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as PMS-DOCETAXEL (DIN 02436388) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 15, 2023	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as ACT DOCETAXEL 40 MG/ML (DIN 02441845) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 24, 2020	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as ACT DOCETAXEL 40 MG/ML (DIN 02444410) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 24, 2020	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TARO-DOCETAXEL (DIN 02465655) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as PMS-DOCETAXEL (DIN 02436361) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 15, 2023	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TARO-DOCETAXEL (DIN 02465647) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TARO-DOCETAXEL (DIN 02465531) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022	—	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as NAT-ERLOTINIB (DIN 02483920) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Oct 1, 2021	May 8, 2019	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as NAT-ERLOTINIB (DIN 02483939) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Dec 1, 2021	May 8, 2019	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as NAT-ERLOTINIB (DIN 02483912) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince May 1, 2021	May 8, 2019	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as APO-ERLOTINIB (DIN 02461889) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 22, 2017	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as APO-ERLOTINIB (DIN 02461862) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 22, 2017	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as APO-ERLOTINIB (DIN 02461870) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 22, 2017	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as PMS-ERLOTINIB (DIN 02454386) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Jul 31, 2025	Jul 28, 2016	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as PMS-ERLOTINIB (DIN 02454394) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 28, 2016	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TEVA-ERLOTINIB (DIN 02377705) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 8, 2014	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TEVA-ERLOTINIB (DIN 02377713) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 8, 2014	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TEVA-ERLOTINIB (DIN 02377691) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 8, 2014	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TARCEVA (DIN 02269007) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 1, 2024	Jan 5, 2007	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TARCEVA (DIN 02269023) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 1, 2024	Jul 19, 2005	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TARCEVA (DIN 02269015) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 1, 2024	Jul 19, 2005	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as FLUOROURACIL INJECTION (DIN 02473763) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 2, 2021	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as TOLAK (DIN 02485346) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 25, 2019	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as FLUOROURACIL INJECTION (DIN 02473771) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 6, 2019	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as ACTIKERALL (DIN 02428946) under ATC L01BC52 FLUOROURACIL, COMBINATIONS. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 19, 2016	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as FLUOROURACIL INJECTION USP (DIN 02413450) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 1, 2014	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as FLUOROURACIL INJECTION USP (DIN 02182742) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Nov 27, 2020	Nov 25, 1998	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as ADRUCIL (DIN 02063921) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 8, 2004	Dec 31, 1995	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as FLUOROURACIL INJ 50MG/ML (DIN 00891754) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996	Dec 31, 1993	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as FLUOROPLEX CREAM 1% (DIN 01982311) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 4, 2011	Dec 31, 1992	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as FLUOROURACIL INJECTION (DIN 00012882) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1989	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as ADRUCIL INJ 50MG/ML (DIN 00428493) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996	Dec 31, 1978	health-canada-dpd
Fluorouracil	CA Health Canada	—	Marketed in Canada as EFUDEX (DIN 00330582) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1975	health-canada-dpd